Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta (Q40134056)

17 September 2017

title

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta (English)

1 reference

17 September 2017

1 reference

Yan H

1

1 reference

17 September 2017

Wang YC

2

1 reference

17 September 2017

Li D

3

1 reference

17 September 2017

Wang Y

4

1 reference

17 September 2017

Liu W

5

1 reference

17 September 2017

Wu YL

6

1 reference

17 September 2017

Chen GQ

7

1 reference

17 September 2017

language of work or name

1 reference

10 May 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

21

1 reference

17 September 2017

issue

7

1 reference

17 September 2017

page(s)

1488-1495

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404735

17 September 2017

exact match

0 references

cites work

Current CML therapy: progress and dilemma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

A practical update on the use of bortezomib in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Involvement of protein kinase C-delta in DNA damage-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Proteasome inhibition as novel treatment strategy in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Arsenic trioxide, a therapeutic agent for APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Regulation of cell death by the Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

Role of Bcr-Abl kinase in resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

7 January 2021

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

7 January 2021

Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

7 January 2021

An alternative 7-ethoxyresorufin O-deethylase activity assay: a continuous visible spectrophotometric method for measurement of cytochrome P-450 monooxygenase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404735

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404735

1 reference

Dimensions Publication ID

17 September 2017

1045785859

0 references

1 reference